TABLE 1

Agonistic and antagonistic activities of E6130 (10 μM) toward chemokine receptors

ReceptorAgonist Mode
% ActivationbAntagonist Mode
% Inhibition
[35S]GTPγS bindinga
 CCR11.615.1
 CCR23.124.9
 CCR3−8.154.8
 CCR4−6.144.0
 CCR6−5.218.7
 CCR70.9−15.2
 CCR88.99.7
 CCR10−5.19.1
 CX3CR195.2−18.6
 CXCR1−2.223.3
 CXCR2−3.49.1
 CXCR32.422.7
 CXCR40.013.2
 CXCR6−1.310.9
 XCR1−4.323.8
β-arrestinc
 CCR2−3−13
 CCR3−25
 CCR4−2−11
 CCR5−20
 CCR6−22
 CCR7−510
 CCR8−115
 CCR9−36
 CCR10−1−15
 CX3CR11790
 CXCR1−1−10
 CXCR2−16
 CXCR3−1−2
 CXCR4310
 CXCR5−24
 CXCR61−10
 ACKR3/CMKOR11570
  • ACKR3/CMKOR1, atypical chemokine receptor 3/chemokine orphan receptor 1.

  • a GTPγS binding assay was performed for chemokine receptors.

  • b Agonist activity of E6130 is expressed as a percentage of the activity of the reference agonists at their EC100 concentrations.

  • c PathHunter β-arrestin assay was performed for chemokine/chemokine-like receptors.